Loading...
Loading...
GLTO| Name | Value |
|---|---|
| Revenues | 1,202.0K |
| Cost of Revenue | 229.0K |
| Gross Profit | 973.0K |
| Operating Expense | 5,722.0K |
| Operating I/L | -5,951.0K |
| Other Income/Expense | -524.0K |
| Interest Income | 340.0K |
| Pretax | -6,475.0K |
| Income Tax Expense | -1,304.0K |
| Net Income/Loss | -6,475.0K |
Galecto, Inc. is a clinical-stage biotechnology company specializing in developing molecules for the treatment of fibrosis, cancer, and inflammation. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis treatment. Additionally, they are developing GB0139, an inhaled galectin-3 inhibitor in Phase IIb for severe fibrotic lung diseases, and GB1211, a selective oral galectin-3 inhibitor in Phase IIa for cancer and Phase Ib/IIa for fibrosis.
